Bank of New York Mellon Corp Increases Position in Audentes Therapeutics, Inc. (NASDAQ:BOLD)

Bank of New York Mellon Corp increased its position in shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) by 36.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,843 shares of the biotechnology company’s stock after buying an additional 5,009 shares during the period. Bank of New York Mellon Corp owned approximately 0.09% of Audentes Therapeutics worth $321,000 at the end of the most recent quarter.

Separately, Wells Fargo & Company MN boosted its stake in shares of Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after buying an additional 5,700 shares during the period. Hedge funds and other institutional investors own 59.76% of the company’s stock.

Shares of Audentes Therapeutics, Inc. (BOLD) traded up 0.16% during trading on Friday, hitting $18.53. The company had a trading volume of 160,428 shares. Audentes Therapeutics, Inc. has a 12-month low of $13.06 and a 12-month high of $22.82. The stock’s market capitalization is $514.84 million. The stock has a 50-day moving average of $19.72 and a 200 day moving average of $16.90.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.10. On average, analysts predict that Audentes Therapeutics, Inc. will post ($3.53) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Bank of New York Mellon Corp Increases Position in Audentes Therapeutics, Inc. (NASDAQ:BOLD)” was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/bank-of-new-york-mellon-corp-has-321000-stake-in-audentes-therapeutics-inc-nasdaqbold-updated.html.

A number of analysts have recently commented on BOLD shares. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Monday, July 17th. ValuEngine upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Wedbush reiterated an “ourperform” rating and issued a $20.00 price objective on shares of Audentes Therapeutics in a research report on Monday, May 15th. Leerink Swann started coverage on Audentes Therapeutics in a research report on Monday, May 1st. They issued an “outperform” rating and a $22.00 price objective for the company. Finally, Evercore ISI started coverage on Audentes Therapeutics in a research report on Wednesday. They issued an “outperform” rating and a $23.00 price objective for the company. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $22.40.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 2,850 shares of the business’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Louis G. Lange sold 15,000 shares of the business’s stock in a transaction on Monday, June 26th. The stock was sold at an average price of $19.78, for a total value of $296,700.00. Following the completion of the transaction, the director now directly owns 470,799 shares in the company, valued at approximately $9,312,404.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,850 shares of company stock worth $653,700. 47.30% of the stock is owned by insiders.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply